title: Abiraterone and increased survival in metastatic prostate cancer.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
authors.forename: Anna
authors.initials: A
authors.lastname: Pia
authors.forename: Massimo
authors.initials: M
authors.lastname: Terzolo
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000736:Androstenes; D000737:Androstenols / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D000324:Adrenocorticotropic Hormone; D013254:Steroid 17-alpha-Hydroxylase; C089740:abiraterone; D011241:Prednisone